Fig. 3

Dropwort treatment sensitizes MSTO-211H cells to MPM conventional chemotherapy. a Upper panel. Viability of MSTO-211H cells pre-treated for 24 h with different doses of Fil.v. extract (6–50 μg/ml) and then treated for 72 h with different doses of CDDP (0–20 μM). Lower panel. Zoom on 0–5 μM CDDP treatment range. Data are represented as mean +/− SD. Statistics (t-test): p < 0.05. b and c Combination index (CI) versus the fractional effect obtained from MSTO-211H cells pre-treated with either 25 μg/ml (b) or 50 μg/ml (c) of Fil.v. extract followed by CDDP treatment (0–20 μM) for 72 h. d Upper panel. Viability of MSTO-211H cells pre-treated for 24 h with different doses of Fil.v. extract (6–12 μg/ml) and then treated for 72 h with different doses of PMTX (0–150 nM). Lower panel. Zoom on 0–50 nM PMTX treatment range. Data are represented as mean +/− SD. Statistics (t-test): p < 0.05. e Combination index (CI) versus the fractional effect obtained from MSTO-211H cells pre-treated with 12 μg/ml of Fil.v. extract followed by PMTX treatment (0–150 nM) for 72 h